Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors
To the best of our knowledge, this is the first description of HBV-related death in patients receiving BTKis from HBV-endemic areas, and the first case of HBV reactivation associated with zanubrutinib despite previous entecavir prophylaxis. Further prospective studies are warranted to develop useful guidelines for monitoring HBV DNA and antiviral prophylaxis to prevent HBV reactivation after BTKi therapy.
Authors
- Je‐Hwan Lee (ORCID: https://orcid.org/0000-0002-7060-1675)
- Han‐Seung Park (ORCID: https://orcid.org/0000-0003-3577-0665)
- Young‐Woong Won (ORCID: https://orcid.org/0000-0001-6209-8339)
- Joon Young Hur (ORCID: https://orcid.org/0000-0003-0092-8370)
- Won Gu Kim (ORCID: https://orcid.org/0000-0002-8404-7759)
- Yunsuk Choi (ORCID: https://orcid.org/0000-0002-7983-8089)
- Jung‐Hye Choi (ORCID: https://orcid.org/0000-0001-5178-6814)
- Jung Hee Lee (ORCID: https://orcid.org/0000-0002-5070-8248)
- Sang Eun Yoon (ORCID: https://orcid.org/0000-0002-2472-8691)
- Seok Jin Kim
- Hyunkyung Park
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- University of Ulsan (KR)
- Hanyang University Guri Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Blood Research
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1007/s44313-025-00093-3
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hanyang University